[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"imipramine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:imipramine":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100575911","phase-2-the-effect-of-topical-imipramine-on-photodynamic-therapy-mediated-immunosuppression-on-forearms-or-face-on-us-veterans-100575911",false,"NCT06778434","The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans","Acid Sphingomyelinase Inhibition to Mitigate the Environmental Exposure Risks of Ultraviolet Light-Induced Actinic Neoplasia and Squamous Cell Carcinoma in US Veterans","Inclusion Criteria:\n\n* Adult Males and Females ages 18 and older who are patients at the Dayton VAMC Dermatology clinics\n* Skin type must be \"Fair\", Fitzpatrick type I or II, due to the presence of actinic damage in this population.\n* Subjects must have a VA physician's order to receive PDT treatment on their forearms.\n* Willing to participate and understand the informed consent document.\n* Willing to avoid excess sun exposure\u002Ftanning beds to the area to be treated with PDT.\n* Has stable transportation to attend study visits at DVA\n\nExclusion Criteria:\n\n* Currently taking any tricyclic antidepressants (TCAs)\n* Currently taking any selective serotonin reuptake inhibitor (SSRI)\n* Has Porphyria\n* Large tattoos in areas to be tested\n* Pregnancy or nursing\n* Taking any oral or topical medications that could interfere with the PDT\n* Active rashes in the areas","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to test the use of topical imipramine in combination with topical photodynamic therapy's (PDT) effect on the effectiveness and pain immunosuppression following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis or \"AK\") on their skin. These are both FDA-approved medications, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using mice that suggest imipramine might reduce immune system suppression by PDT thus allowing it to work better. Subjects whose provider has decided that they may benefit from PDT to treat their skin due to many AK precancerous lesions will be recruited for this study. Please note that the PDT itself is not experimental, only the imipramine treatment to the skin. There is a separate informed consent for the PDT.",[26,27,28],"Actinic Keratosis","Imipramine","Photodynamic Therapy","RECRUITING","2025-12-18",{"date":32,"type":33},"2025-12-22","ACTUAL",{"date":35,"type":33},"2025-04-01",{"date":37,"type":20},"2029-03-30",{"name":39,"class":40},"VA Office of Research and Development","FED",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100492189","phase-1-the-effect-of-topical-imipramine-on-pain-and-effectiveness-of-topical-photodynamic-therapy-100492189","NCT05688904","The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","Pilot Studies Testing the Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","Inclusion Criteria:\n\n* Male or female ages 18 and older\n* Skin type must be \"Fair\", Fitzpatrick type I to III, due to the presence of actinic damage in this population.\n* Subjects need to have a physician's order to receive PDT treatment on their face, scalp or forearms.\n* Willing to participate and understand the informed consent document.\n* Willing to avoid excess sun exposure\u002Ftanning beds to the area to be treated with PDT.\n\nExclusion Criteria:\n\n* Those currently taking any tricyclic antidepressants (TCAs)\n* Those currently taking any selective serotonin reuptake inhibitor (SSRI)\n* Those with porphyria\n* Large tattoos in the treated areas\n* Pregnancy or nursing\n* Taking any oral or topical medications that could interfere with the PDT (Appendix A)\n* Active rashes in the area",{"count":50,"type":20},24,[52],"PHASE1","The purpose of this study is testing the use of topical Imipramine in combination with topical photodynamic therapy's (PDT) effect on pain following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis-AKs) on their skin. These are both FDA-approved treatments, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using animals that suggest that imipramine might make the PDT less painful and might help it work better. In order to participate, the subject and their dermatologist have decided that they would benefit from PDT to treat their skin due to many AK precancerous lesions. Please note that neither PDT nor imipramine are experimental treatments, but treating their skin with imipramine before PDT is a new approach.",[27,28,26],"2024-04-23",{"date":57,"type":33},"2024-04-24",{"date":59,"type":33},"2023-01-19",{"date":61,"type":20},"2028-03",{"name":63,"class":64},"Wright State University","OTHER"]